Skip to content

Stock-Based Comp at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
Revvity logo
RevvityRVTY
Mesa Laboratories logo
Mesa LaboratoriesMLAB
Illumina logo
IlluminaILMN
CareDx logo
CareDxCDNA

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s stock-based comp?
Fulgent Genetics, Inc. (FLGT) reported stock-based comp of $9.89M in Q1 2026.
How has Fulgent Genetics, Inc.'s stock-based comp changed year-over-year?
Fulgent Genetics, Inc.'s stock-based comp decreased by 6.3% year-over-year, from $10.55M to $9.89M.
What is the long-term trend for Fulgent Genetics, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s stock-based comp has grown at a 25.6% compound annual growth rate (CAGR), from $15.88M to $39.58M.